Resultados de procura - David E. Allison

  • Mostrando 1 - 6 Resultados de 6
Limitar resultados
  1. 1
    Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

    Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial por Kelong Han, Jin Jin, Mauricio Maia, John Lowe, Martina Sersch, David E. Allison

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Population pharmacokinetics of bevacizumab in cancer patients with external validation

    Population pharmacokinetics of bevacizumab in cancer patients with external validation por Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie Gosselin, Sandhya Girish, David E. Allison, Jin Jin

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer por David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Y. Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey, Gwen Fyfe

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy

    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progress... por David B. Agus, Christopher J. Sweeney, Michael J. Morris, David S. Mendelson, Douglas G. McNeel, Frederick R. Ahmann, Jin Wang, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, Michael W. Kattan, Howard I. Scher

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Charge variants in IgG1

    Charge variants in IgG1 por Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson, Zephania W. Kwong, Jihong Yang, Xiangdan Wang, Zhenling Yao, Alavattam Sreedhara, Tony Cano, Devin B. Tesar, Ihsan Nijem, David E. Allison, Pin Yee Wong, Yung‐Hsiang Kao, Cynthia Quan, Amita Joshi, Reed J. Harris, Paul A. Motchnik

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status por Michael S. Gordon, Daniela Matei, Carol Aghajanian, Ursula A. Matulonis, Molly Brewer, Gini F. Fleming, John D. Hainsworth, Agustin A. García, Mark D. Pegram, Russell J. Schilder, David E. Cohn, Lynda D. Roman, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, David A. Eberhard, Thinh Q. Pham, Randall C. Dere, Beth Y. Karlan

    Publicado 2006
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: